Trishula Therapeutics was launched to be dedicated to the development of TTX-030, a first-in-class anti-CD39 antibody, being studied in advanced cancers. The new company is designed to further progress and focus on the existing TTX-030 development collaboration with AbbVie.
The Trishula launch is the result of the spin out of the TTX-030 program from Tizona Therapeutics with funds and employees to support its development. Shares in Trishula were distributed to Tizona shareholders, including MPM, Canaan, Abingworth, Lightstone, Interwest Partners, and AbbVie Ventures. Tizona’s current chief executive officer, Scott Clarke, will join the Trishula board and serve as its initial chief executive officer. Clarke will be joined by a seasoned team of experts focused on TTX-030, which is currently being studied in phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancer.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“As a stand-alone company, Trishula will continue to deliver on the mission of bringing TTX-030, a novel, transformational medicine, to cancer patients in great need,” said Scott Clarke, CEO, Trishula. “I have complete confidence that TTX-030 will continue to rapidly and effectively advance within Trishula and in partnership with AbbVie.”